The initial step in viral infection is attachment of the virus to cellular receptors (6) . Receptors may be complexes that serve as targets for several ligands (e.g., receptor for Epstein-Barr virus and complement C3d [9] ). For reovirus type 3, a receptor has been isolated that appears to closely resemble that utilized by ,-adrenergic ligands (4, 5) . That the 3-adrenergic receptor functions as a reovirus receptor has been questioned, primarily on the basis of the failure of virus to interfere with either P-adrenergic agonist activation of adenylate cyclase or ligand (antagonist) binding (3) . Also, a receptor that mediates common, high-affinity binding for both reovirus types 1 and 3 on endothelial cells was recently described (26) . The results of our experiments, however, support the reovirus type 3-i-adrenergic receptor interaction and suggest that reovirus type 3 infects cells via the P-adrenergic antagonist, but not agonist, binding site.
MATERIALS AND METHODS
Tissue-cultured cells. Y1 mouse adrenal (23) , C6 rat glial (8) , and mouse L cells were grown and maintained in Ham nutrient mixture F10 supplemented with 15% horse serum and 2.5% fetal calf serum in a humidified atmosphere of 95% air-5% CO2 at 37°C.
Viruses. Reovirus type 3 (Dearing strain) was purchased from the American Type Culture Collection (Bethesda, Md.). Virus stocks were prepared from infected L-cell tissue culture supernatants that had been clarified by low-speed centrifugation.
Encephalomyocarditis virus (EMC) was originally obtained from Albert Notkins (National Institutes of Health, Bethesda, Md.). After three cycles of plaque purification, virus stocks were propagated in mouse embryo cells. Virus stocks for these experiments contained 1.7 x 107 PFU/ml (8) . Murine cytomegalovirus (MCMV) was obtained from M. C. Jordan (University of Minnesota, Minneapolis). Virus stock of MCMV, prepared from tissue culture supernatants of mouse embryo cells, contained 106 PFU/ml (23) .
Concentrates of reovirus and EMC were prepared from infected tissue culture supernatants with 6% (wt/vol) polyethylene glycol (molecular weight, 6,000 to 8,000) for 120 min, followed by centrifugation at 16 or absence of 100 ,ug of unlabeled haloperidol. After washing, the cells were lysed with 1% sodium dodecyl sulfate, and the 3H-spiperone bound was determined.
To assess agonist function, isoproterenol (10-7 to 10-9 M) was added to C6 cells in F10 medium without serum and incubated for 10 or 20 min at 370C in the presence or absence of 75 ,ug of reovirus and 1 mM 3-O-methylxanthine (Sigma Chemical Co., St. Louis, Mo.). The medium was assayed for cyclic AMP, using a commercial radioimmunoassay (Dupont, NEN).
RESULTS
Specificity of virus inhibition. After preliminary experiments, which demonstrated inhibition by reovirus of 3H-DHA binding to L cells, additional experiments were conducted to determine whether other viruses could also inhibit such binding to these cells and to other cell types. Reovirus type 3 inhibited the binding of the P-adrenergic antagonist ligand to all three cell types tested. In contrast, EMV and MCMV had no effect on 3H-DHA binding. The results for mouse L cells are shown in Table 1 . The degree of inhibition of 3H-DHA binding was related to the amount of virus used ( Table 2 ). Amounts of virus equivalent to less than 25 ,ug of viral protein were without effect.
Specificity of ligand inhibition by reovirus. To assess whether the reovirus type 3 inhibition was specific to ,Badrenergic ligands, the ability of the virus to interfere with other, related and unrelated ligand binding was examined. Reovirus did not inhibit binding of the dopaminergic ligand 3H-spiperone (Table 2) or that of cholera toxin (results not shown).
Effect of reovirus on agonist function. The functional interactions of reovirus with ,-adrenergic agonists and their receptors were also examined. When reovirus was incubated with C6 glial cells, it neither activated adenylate cyclase nor interfered with isoproterenol-induced activation of adenylate cyclase (Table 3) . Additional experiments using isoproterenol concentrations as low as 10-9 M confirmed the lack of inhibition by reovirus (data not shown).
DISCUSSION
The receptor for reovirus type 3 appears to closely resemble that for ,B-adrenergic ligands (5, 10, 16). There may be Other recent reports have also documented that reovirus does not induce adenylate cyclase activity or interfere with P-adrenergic agonist-induced activation of adenylate cyclase (10, 16) . With use of antiidiotype antireceptor antibodies and isolated receptor, a ,B-adrenergic antagonist ligand (iodocyanopindolol) was able to bind to receptors already binding antiidiotype antibody, leading to the conclusion that reovirus type 3 and 3-adrenergic ligands bind to distinct domains on the receptor (10, 16) . In these studies, however, virus itself was not used to compete with ,B-adrenergic ligand, and it is possible that the kinetics of binding of antibody differ from those of virus or ,-adrenergic ligand. The kinetics of binding of P-adrenergic antagonists are quite complex (1, 13) , and it is likely that ,B-adrenergic binding by antagonists differs from that of agonist ligands (25) . Our conditions were such that we were able to observe competition by reovirus for ,-adrenergic antagonist binding, suggesting utilization of a common receptor domain for virus and antagonist ligand, but these observations do not permit the conclusion that the same receptor epitopes are shared by both virus and antagonist ligand. Ligand-induced conformational changes may lead to interactions more complex than simple competitive binding (25) .
Recently as well, a 54-kilodalton receptor was found to mediate high-affinity binding for both reovirus types 1 and 3 on endothelial cells (26) . The relationship between this receptor and epitopes present on the ,-adrenergic receptor needs further investigation.
Our results, therefore, are consistent with the conclusion that reovirus type 3 binds to P-adrenergic receptors but to only those domains occupied by antagonist, not agonist, ligands. Approaches using monoclonal antibodies against the receptor complex, similar to studies conducted with EpsteinBarr virus and the complement receptor (9) 
